This article is more than 5 years old. Information may no longer be current.
Aerie acquires PRINT technology from Envisia
Click Here to Manage Email Alerts
Aerie Pharmaceuticals has acquired the rights to Envisia Therapeutics’ PRINT technology, according to an Aerie press release.
The PRINT technology system creates sustained-release products utilizing fully scalable manufacturing processes, the release said. Aerie plans to use it to “accelerate the advancement of its pipeline to treat conditions in the back of the eye,” including wet age-related macular degeneration and diabetic retinopathy.
Aerie initially will use the technology to make injectable implants containing AR-13154, its preclinical product candidate.
Additionally, Aerie has acquired the intellectual property rights to ENV1105, Envisia’s preclinical dexamethasone steroid product candidate for the treatment of diabetic macular edema.
Envisia will receive an initial $25 million in cash and Aerie stock, with the potential to earn additional payments subject to product approval milestones.